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Abstract
Background: The aim of this study was to analyze the influence of volumetric changes of bladder and rectum
filling on the 3D dose distribution in prostate cancer radiotherapy.
Methods: A total of 314 cone-beam CT (CBCT) image data sets from 19 patients were enrolled in this study.
For each CBCT, the bladder and rectum were contoured and volume sizes were normalized to those on their
original CT. The daily delivered dose was recalculated on the CBCT images and the doses to bladder and rectum
were investigated. Linear regression analysis was performed to identify the mean dose change of the volume
change using SPSS 19.
Results: The data show that the variances of the normalized volume of the bladder and the rectum are 0.13–0.58
and 0.12–0.50 respectively. The variances of V70Gy, V60Gy, V50Gy, V40Gy and V30Gy of bladder are bigger than those of
rectum for 17 patients. The linear regression analysis indicates a 10 % increase in bladder volume will cause a 5.6 %
(±4.9 %) reduction in mean dose (p <0.05).
Conclusions: The bladder’s volume change is more significant than that of the rectum for the prostate cancer
patient. The rectum volume variations are not significant except for air bubbles, which change the shape and the
position of the rectum. The bladder volume variations may cause dose changes proportionately. Monitoring the
bladder’s volume before fractional treatment delivery will be crucial for accurate dose delivery.
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Background
Most radiotherapy patients with prostate cancer are
treated with intensity modulated radiotherapy (IMRT).
Especially volumetric modulated arc therapy (VMAT)
helps to get highly conformal dose distributions for the
planning target volume (PTV) while minimizing the
dose given to the organs at risk and with short delivery
time. However, the advantages of IMRT and VMAT are
limited by daily treatment uncertainties [1–3]. Daily
treatment uncertainties include daily patient setup errors
and internal organ motion and deformation. Studies on
prostate motion have shown that both the position and
the shape of the prostate vary throughout the course of
treatment [4, 5].
Currently, CBCT is a popular imaging method that
provides valuable 3D information of the patient in treat-
ment position [6–8]. In our hospital, we commissioned an
Elekta Synergy VMAT accelerator with on-board kV-
CBCT in 2011, which was used to improve the geometric
accuracy of target localization in radiation therapy. In
principle, CBCT can be used for dose calculation. Richter
et al. reported small dose differences between planning CT
and CBCT with 0.9 % ± 0.9 % for pelvis, 1.8 % ± 1.6 % for
thorax and 1.5 % ± 2.5 % for head [9]. In our institution,
Hu et al. showed the feasibility of using a region-of-interest
(ROI) mapping method for accurate CBCT-based dose
calculation [10].
Both rectum and bladder volumes change during the
course of radiotherapy for prostate cancer. Roeske et al.
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observed that bladder and rectal volumes varied by
±30 % according to treatment planning computed
tomography [11]. Huang et al. used CBCT to analyze
the changes of the bladder and rectum during fraction-
ated radiotherapy of the prostate. The differences in the
volume and radiation dose were 44 %(±41) and
18 %(±17) for the bladder and 36 %(±29) and 22 %(±15)
for the rectum [12]. During the course of image-guided
radiotherapy in the post-prostatectomy, Akin et al.
assessed the dose-volume parameters (V40%, V50%, V60%,
V65%) for the bladder and rectum, and found the most
actual doses delivered were higher than calculated in the
treatment planning CT: the V40%, V50%, V60% and V65% of
the bladder were 20 % more higher than calculated in
the treatment planning CT, the V40% of rectum is 8.7 %
higher than the calculated in the treatment planning CT,
and the V60% of rectum is 59.6 % higher than calculated
in the treatment planning CT, while the V50% and V60%
of rectum did not show significant difference [13].
The purpose of this study is to track the volume and
dosimetric changes in the bladder and rectum based on
daily cone-beam CT for prostate radiotherapy. We hope




Nineteen prostate cancer patients were included in this
study. Of these, 16 patients with stage T1-3 N0M0 had
radiotherapy (RT) with total prescribed dose from 70.2
to 79.2 Gy by 1.8 Gy per fraction. Three patients with
biochemical failure after prostatectomy had salvage RT
with a total prescribed dose of 64.8 Gy by 1.8 Gy per
fraction. For patients with radical RT, the clinical target
volume (CTV) was defined as the prostate gland and
seminal vesicle as visible on the CT scan. For patients
with salvage RT, the CTV included the prostate and
seminal vesicle bed. The planned target volume (PTV)
was defined as CTV plus 5 mm in the posterior direc-
tion and 8 mm for all other directions. The rectum,
bladder, femoral heads were also contoured for each pa-
tient. The patients were required to drink a glass of
water about 30 mins before the acquisition of treatment
planning CT under the supervision of physicians. Also,
the patients were reminded to drink the same amount of
water 30 mins before each fractional treatment. The
VMAT plan optimization and dose calculation was car-
ried out in the treatment planning system Pinnacle3
(Philips Pinnacle3 V8.0d, Fitchburg, WI, USA). The im-
aging protocol consisted of a planning CT (AcQsim CT
Simulator, Philips Medical System, Cleveland, OH) and
daily CBCTs (Elekta, Synergy S, XVI, Crawley, UK) ac-
quired in treatment position. The following parameters
of CT and CBCT were used for imaging: CT: 120kVp,
high-resolution reconstruction (512 * 512), with a slice
thickness of 5 mm; CBCT: 120kVp, FilterType ‘M’, re-
construction resolution (410 * 410), with a slice thick-
ness of 3 mm. Each patient’s CBCT database contained
8–27 CBCTs. Most of the patient’s CBCTs were acquired
once every 2 days or twice a week or twice in 3 days.
One patient only had the first ten CBCTs during the
treatment course. A total of 314 CBCTs are included in
this study. The same physician delineated the bladders
and rectums for consistency.
Dose calculation on CBCT
To calculate the “dose of the day” and assess the dose to
the bladder and rectum, the CBCTs were rigidly auto-
aligned to the planning CT using RayStation treatment
planning system (Version 3.0, RaySearch Laboratories
AB, Stockholm, Sweden). All the original planning data
including the CT data sets, RT structures, and RT plans
were exported to the RayStation treatment planning
system for dose recalculation. The same Synergy
machine was commissioned in the RayStation and the
recalculated dose distributions between the Pinnacle and
RayStation were verified within 1.5 %. Due to the recal-
culations of the dose on CBCT were performed in the
RayStation, the original dose distributions on CT were
also recalculated in RayStation which used as plan dose,
and comparisons were performed on the same TPS for
reliability purpose. In order to use CBCT images for
dose calculation, the image pixel values were converted
from CBCT numbers to physical density using the ROI
CT number mapping method as reported [10]. A brief
description of the ROI CT number mapping method is
as follows: 1) The CBCT images and the CT images of
the same patient were acquired on the same day to
minimize the change in patient anatomy between the
two images. 2) The CT and CBCT images were regis-
tered in the RayStation TPS. 3) The ROIs were mapped
from CT to the CBCT, and the mean CBCT number
values of the ROIs were recorded. 4) Generate the
CBCT numbers to physical density calibration curve
based on the density values measured on the CT. After
that, the original plan was rigidly copied to the CBCT
image data set for dose recalculation.
Dose and volume evaluation
All bladder and rectum volumes on the CBCTs were nor-
malized to those on the original CT to track the volume
changes. Additionally, the bladder and the rectum were
mapped to the planning CT using MIM software version
6.1(MIM Software Inc., Cleveland, OH, USA) to visualize
the deformation of the bladder and rectum. The V70Gy,
V60Gy, V50Gy, V40Gy, V30Gy, V20Gy and V10Gy for the rectum,
and V70Gy, V60Gy, V50Gy, V40Gy and V30Gy for the bladder
were calculated respectively. The deviation of the mean
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dose to the bladder and rectum were also evaluated. A
linear regression analysis was performed to identify the
mean dose change vs. the volume change using SPSS
version 19.0 (SPSS, Inc., Chicago, IL, USA). The mean
doses and volumes were all normalized to their corre-
sponding dose and volume on the original plan.
Results
Volume evaluation
For each patient, the volumes of bladder and rectum on
the CBCT were different to those on the planning CT.
The deformation of the bladder and the rectum could be
clearly identified. Figure 1(a)–(b) show bladder and
rectum contours for one patient derived from the differ-
ent CBCTs projected on one DRR. The corresponding
DVHs are displayed as well. Figure 1(c) demonstrates
different projections of the bladder contours on one
DRR for a patient who had only very slight changed in
his bladder filling. The result from the nineteen patients
show that the variance of the normalized volume
(normalized to corresponding OARs in planning CT) of
the bladder is 0.13–0.58 and the rectum is 0.12–0.50.
Figure 2 shows the variance of the bladder and the
rectum for all the patients. Among the 19 patients, 13
Fig. 1 DRR of two patients. a–b show bladder and rectum contours for one patient derived from the different CBCTs projected on one DRR.
The corresponded DVHs are displayed as well. c demonstrates different projections of the bladder contours on one DRR for a patient who had
only very slight changed in his bladder filling
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patients’ variances of volumes for the rectum are smaller
than those of the bladder. But in terms of absolute vol-
ume, the variances of the rectum are all smaller than the
bladder.
Dose evaluation
Figure 3(a)–(b) represent dose distribution of the same
transversal plane of the same patient in one of CBCT
and CT, respectively. Figure 3(d) displays the dose differ-
ence between Fig. 3(a) and (b). The dose difference area
can be seen on Fig. 3(d) because of the air bubbles which
appeared on the CBCT images. The major dose differ-
ences which occur around the patient surface are mainly
caused by position error and deformation that occurred
between fractional CBCT and planning CT. Because the
volume of the rectum varies less than the bladder, as
shown in Fig. 4, the results from the 19 patients demon-
strate that the standard deviation of V70Gy, V60Gy, V50Gy,
V40Gy and V30Gy of the bladders are bigger than those of
the rectum for all of the patients except for two. In six
of the 19 patients, mean V70Gy of the CBCTs are >20 %.
Dose and volume relationship
Figure 5 displays the regression analysis between the
normalized mean dose and the normalized volume for
each patient’s bladder. The result of the linear regression
analysis shows that the mean dose of the bladder would
increase while the volume of the bladder shrinks (all
with p <0.05), but find no correlation for the rectum
(seven patients p <0.05, five of them show positive cor-
relation). On average, the slope of the linear relationship
between the mean dose and the volume of the bladder is




Fig. 3 a–b represent dose distribution of the same transversal plane of the same patient in one of CBCT and CT respectively. c shows the DVH of
the (a) (solid line) and (b) (dash line). d displays the dose difference between the (a) and (b)
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0.56 ± 0.49, which means if the bladder volume is in-
creased by 10 %, the mean dose will reduce by 5.6 %
(±4.9 %).
Discussion
Previous works showed that the position and shape of
the bladder and rectum vary throughout the course of
prostate radiotherapy treatment [14–16]. The applica-
tion of CBCT can improve the accuracy of radiation
therapy in target location and dose delivered [17, 18]. In
this study, we used CBCT for patient dose recalculation
and organs at risk evaluation. Although patient setup
error can be corrected through the rigid registration, de-
formations like the air bubbles in the rectum and the
volume variance of the bladder appear to be more im-
portant. Fortunately, these deformations only affect the
dose distribution slightly in the central area of the pa-
tient. The maximum dose difference between initial
treatment plan and recalculated dose for the CBCT in
the central area is no more than 3.50 Gy, about 5.1–
4.2 % of the prescription dose (64.8–79.2 Gy) to the
PTV. Therefore, the CTV dose coverage would be suffi-
cient if the CTV does not move out of the PTV area
(projected from the original planning CT). It’s necessary
to start to monitor the rectum and bladder filling at the
treatment planning CT. If rectum and bladder filling are
not sufficient, the treatment delivery should be rejected.
The most significant variation in dose area is caused
by the air bubbles, which expands the rectum closer to
the target. This is one major reason for variations which
appeared in rectum dose-volume value. Moreover, the
image quality of CBCT suffers from the air bubbles,
which blurs the boundary of the rectum and causes un-
certainty both on contouring and dose evaluation. Pad-
hani et al. had subjectively graded 5 levels of rectal air/
fecal distension and found the moderate and large
grades, similar to the cases with air bubbles in this study,
were the most likely to produce rectal movements [19].
He suggested that patients should be advised to empty
their rectum prior to radiotherapy to reduce rectal dis-
tension. To increase the accuracy of the dose distribu-
tion, the patients should empty the rectum before
radiotherapy treatments.
Bladder shrinkage and expansion are two key factors
for dose variances, but are hard to control, especially in
cancer centers without careful bladder filling exam. This
study found that most patients’ bladder volume varied
during treatment. What’s more, bladder volumes of
three patients were all smaller than their original state,
while in one patient the opposite case was true. Perhaps
some patients may not feel comfortable holding urine
and did not realize the importance of drinking water to
keep the bladder full, so they did not always drink water.
Furthermore, some patients may be too nervous and
therefore drank more water, making the bladder full. In
our hospital, there are too many patients that need to be
treated, so physicians and technicians may not always be
able to relax the patient or confirm whether the patient
drink water before treatment. Patients could not keep
the bladder volume constant during each fraction treat-
ment while the air bubbles only existed in a few CBCTs
during the treatment course, which might result in the
volume of the bladder vary more than the rectum in this
study. An increase of 10 % of bladder volume will cause
to a 5.6 % reduction of mean dose. This indicates that
some new method with quick bladder volume evaluation
will be useful for ensuring the accurate dose delivery
and sparing the bladder. As Fig. 3 shows, the shape of
the rectum can experience irregular changes because of
the air bubbles which can decrease the chances of find-
ing a statistical association between the rectum volume
and the mean dose.
There are several studies which have sought to define
normal tissue dose constraints based on retrospective
analyses of dose-volume and toxicity relationships. Ped-
erson et al. found that the rate of Grade 2+ gastrointes-
tinal (GI) toxicity were correlated to V70Gy, V65Gy and
V40Gy of the rectum. Freedom from Grade 2+ GI toxicity
at 4 years was 100 % for men with rectal V70Gy < 10 %,
V65Gy < 20 %, and V40Gy < 40 %; 92 % for men with rectal
V70Gy < 20 %, V65Gy < 40 %, and V40Gy < 80 %; and 85 %
for men exceeding these criteria [20]. Another study
showed that the risk of chronic rectal toxicity Grade >=
2 for rectal with V70Gy < 15 % was 9 %, V70Gy between 25
and 40 % was 18 % and V70Gy >40 % was 25 % [21]. They
all pointed out that the higher the rectal volume receiv-
ing high doses (>40 Gy), especially 70 Gy, the higher the
probability that the patient would get Grade 2+ GI. This
suggests that when using CBCT to improve the accuracy
Fig. 4 The average of standard deviation of the V70Gy, V60Gy, V50Gy,
V40Gy and V30Gy of the bladders and the V70Gy, V60Gy, V50Gy, V40Gy,
V30Gy, V20Gy and V10Gy of the rectum for the all 19 patients
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Fig. 5 The regression analysis between the normalized mean dose and the normalized volume for each patient’s bladder
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of the target location, we should also consider keeping
the rectum from the high dose area in order to reduce
the risk of Grade 2+ GI. As for the bladder, only a few
studies found dose-volume relationships associated with
the risk of GU toxicity [22]. Perhaps the changes in blad-
der filling cause changes in bladder DVH parameters
which make the establishment of a relationship between
the dose-volume and GU toxicity difficult. But it is still
important to reduce the volume of bladder which enters
the high dose area when using the CBCT to set the pa-
tient’s position.
In this study, we only focused on dose verification of
the bladder and the rectum for those treated patients.
Our results suggest that the current patient instruction
with only drink a glass of water is not sufficient to
ensure the bladder filling in a busy center. Pretreatment
CBCT imaging or quick bladder volume evaluation tool
is required for accurate treatment delivery. Especially for
the quick bladder volume evaluation tool without
additional imaging dose and patient setup time will be a
good option for busy center.
Conclusion
This study used daily cone-beam CT to evaluate the
volume changes of bladder and rectum and evaluate the
dosimetric changes of bladder and rectum. Our results
demonstrate that the volume change of the bladder is more
significant than changes in rectal volume for prostate
cancer patients. The volume changes of the rectum are not
significant except for the air bubbles in the rectum, but
bladder volume variations will cause bladder dose changes
proportionately. The mean dose received to the bladder
will decrease with enlarging the volume. In addition, the
CTV will still be covered by the isodose of 95 % of
prescription dose during the treatment course.
Abbreviations
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